US20010047014A1 - Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists - Google Patents

Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists Download PDF

Info

Publication number
US20010047014A1
US20010047014A1 US09/811,888 US81188801A US2001047014A1 US 20010047014 A1 US20010047014 A1 US 20010047014A1 US 81188801 A US81188801 A US 81188801A US 2001047014 A1 US2001047014 A1 US 2001047014A1
Authority
US
United States
Prior art keywords
acid
compound
benzyl
disease
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US09/811,888
Other versions
US6432985B2 (en
Inventor
Alexander Alanine
Bernd Buettelmann
Marie-Paule Neidhart
Georg Jaeschke
Emmanuel Pinard
Rene Wyler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoffmann-La Roche Inc
Original Assignee
Hoffmann-La Roche Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP00108769.1 priority Critical
Priority to EP00108769 priority
Priority to EP00108769 priority
Application filed by Hoffmann-La Roche Inc filed Critical Hoffmann-La Roche Inc
Assigned to F. HOFFMANN-LA ROCHE AG reassignment F. HOFFMANN-LA ROCHE AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ALANINE, ALEXANDER, BUETTELMANN, BERND, HEITZ NEIDHART, MARIE-PAULE, JAESCHKE, GEORG, PINARD, EMMANUEL, WYLER, RENE
Assigned to HOFFMANN-LA ROCHE INC. reassignment HOFFMANN-LA ROCHE INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: F. HOFFMANN-LA ROCHE AG
Publication of US20010047014A1 publication Critical patent/US20010047014A1/en
Publication of US6432985B2 publication Critical patent/US6432985B2/en
Application granted granted Critical
Application status is Expired - Fee Related legal-status Critical
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/48Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4

Abstract

The invention relates to a compound of the formula
Figure US20010047014A1-20011129-C00001
its R,R-, S,S-enantiomers and racemic mixtures thereof and to their pharmaceutically acceptable acid addition salts.
The compound of formula I and its R,R- and S,S-enantiomers may be used as medicaments for the treatment of diseases, wherein the therapeutic indications include acute forms of neurodegeneration caused by stroke or brain trauma; chronic forms of neurodegeneration such as Alzheimer's disease, Parkinson's disease, Huntington's disease or ALS (amyotrophic lateral sclerosis); neurodegeneration associated with bacterial or viral infections, and, diseases such as schizophrenia, anxiety, depression and chronic/acute pain.

Description

    FIELD OF INVENTION
  • The present invention is generally related to substituted piperidine compounds and more particularly to compounds with activity as NMDA receptor subtype selective blockers that have low activity as blockers of hERG potassium channels. [0001]
  • The present invention relates to the compound of formula [0002]
    Figure US20010047014A1-20011129-C00002
  • to its R,R- and S,S-enantiomers and to their pharmaceutically acceptable acid addition salts. [0003]
  • The compounds of the present invention are NMDA (N-methyl-D-aspartate)-receptor-subtype selective blockers, which have a key function in modulating neuronal activity and plasticity which makes them key players in mediating processes underlying development of CNS including learning and memory formation and function. [0004]
  • Under pathological conditions of acute and chronic forms of neurodegeneration overactivation of NMDA receptors is a key event for triggering neuronal cell death. NMDA receptors are composed of members from two subunit families, namely NR-1 (8 different splice variants) and NR-2 (A to D) originating from different genes. Members from the two sub-unit families show a distinct distribution in different brain areas. Heteromeric combinations of NR-1 members with different NR-2 sub-units result in NMDA receptors, displaying different pharmacological properties. Possible therapeutic indications for NMDA receptor subtype specific blockers include acute forms of neurodegeneration caused, e.g., by stroke or brain trauma; chronic forms of neurodegeneration such as Alzheimer's disease, Parkinson's disease, Huntington's disease or ALS (amyotrophic lateral sclerosis); neurodegeneration associated with bacterial or viral infections, diseases such as schizophrenia, anxiety and depression and acute/chronic pain. [0005]
  • Objects of the present invention are novel compounds of formula I, its R,R- and S,S-enantiomers, racemic mixtures of these enantiomers and pharmaceutically acceptable salts of these novel compounds; their use in the treatment or prophylaxis of diseases caused by overactivation of respective NMDA receptor subtypes, which include acute forms of neurodegeneration caused, e.g., by stroke or brain trauma; chronic forms of neurodegeneration such as Alzheimer's disease, Parkinson's disease, Huntington's disease or ALS (amyotrophic lateral sclerosis); neurodegeneration associated with bacterial or viral infections, and diseases such as schizophrenia, anxiety, depression and acute/chronic pain; the use of these compounds for manufacture of corresponding medicaments; processes for the manufacture of these novel compounds; and medicaments containing the compounds of the invention. [0006]
  • The term “pharmaceutically acceptable acid addition salts” embraces salts with inorganic and organic acids, such as hydrochloric acid, nitric acid, sulfuric acid, lactic acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methane-sulfonic acid, p-toluenesulfonic acid and the like. [0007]
  • 4-Hydroxy-piperidin derivatives are described, for example in EP 824 098, in which the piperidine ring is substituted by one hydroxy group in 4-position. These compounds are described to possess activities on the NMDA receptor and are useful in the treatment of acute forms of neurodegeneration caused, for example, by stroke and brain trauma, and chronic forms of neurodegeneration such as Alzheimer's disease, Parkinson's disease, ALS (amyotrophic lateral sclerosis), neurodegeneration associated with bacterial or viral infections and acute/chronic pain. [0008]
  • It is known from EP 824 098 that these compounds are good NMDA receptor subtype specific blockers with a high affinity for NR2B subunit containing receptors and low affinity for NR2A subunit containing receptors. [0009]
  • Activity versus α[0010] 1-adrenergic receptors is also low and the compounds are active in vivo against audiogenic seizures in mice in the low mg/kg range. Importantly, these compounds were neuroprotective in an animal stroke model, namely, a permanent occlusion of the middle cerebral artery. However, in vitro and in vivo cardiotoxicity studies showed that these compounds had the propensity to prolong cardiac action potential duration in vitro and consequently the ‘QT’-interval in vivo and thus, had a potential liability to produce cardiac arrhythmias. The ability of such compounds to prolong the cardiac action potential was identified as being due to an action at the hERG type potassium channel, which is important for action potential repolarisation in humans and other species, and most compounds known to prolong the QT-interval in man are active at blocking this channel. Thus, the compounds of the prior art block heterologously recombinant human ERG potassium channels.
  • It has now surprisingly been found that the following preferred compounds of formula I (3R,4R) and (3S,4S)-4-benzyl-[2-(4-hydroxy-phenoxy)-ethyl]-piperidine-3,4-diol, (3R,4R)-4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidine-3,4-diol and (3S,4S)-4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidine-3,4-diolare NMDA NR2B subtype selective antagonists. These preferred compounds of the invention share the highly specific subtype selective blocking properties of compounds of the prior art, for example of 1-[2-(4-hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol (EP 824 098), and are neuroprotectants in vivo, unlike the compounds of EP 824098, the preferred compounds of the invention are significantly less active as blockers of the hERG potassium channels and, thus, are much less likely to have pro-arrhythmic activity in man. [0011]
  • In the following table the high selectivity of compounds of the present invention is demonstrated. [0012]
    Selectivity profile of NMDA NR2B subtype selective antagonists
    Inhibition of Inhibition of Inhibition of
    [3H]-Ro 25- [3H]-Prazosin hERG K+ current
    6981 binding binding IC50 (μM) (effect
    Compound IC50 (μM)a IC50 (μM)b (%) at 10 μMc)
    EP 824098 0.010 3.5 0.69 μM
    1-[2-(4-hydroxy-
    phenoxy)-ethyl]-4-
    (4-methyl-benzyl)-
    piperidin-4-ol
    I (racemate) 0.045 27 >10 μM (45%),
    I-1 (R,R) 0.038 25 >10 μM (44%)
    I-2 (S,S) 0.039 30 >10 μM (40%)
  • The novel compounds of formula I and their pharmaceutically acceptable salts can be prepared by methods known in the art, for example by a process described below, which process comprises [0013]
  • reacting a compound of formula [0014]
    Figure US20010047014A1-20011129-C00003
  • with a compound of formula [0015]
    Figure US20010047014A1-20011129-C00004
  • and deprotecting the hydroxy group to give compounds of formulae [0016]
    Figure US20010047014A1-20011129-C00005
  • and, preferably, converting the compounds obtained into a pharmaceutically acceptable acid addition salts. [0017]
  • In accordance with the described process variant, 4-benzyl-3,4-dihydroxy-piperidine, (3R,4R)-4-benzyl-3,4-dihydroxy-piperidine or (3S,4S)-4-benzyl-3,4-dihydroxy-piperidine is treated with 1-benzyloxy-4-(2-chloro-ethoxy)-benzene in the presence of K[0018] 2CO3. The reaction is carried out at about 80-100° C. The O-protecting group is then cleaved off in conventional manner, for example by hydrogenating in the presence of Pd/C.
  • The acid addition salts of the compounds of formula I are especially well suited for a pharmaceutical use. [0019]
  • The following schemes 1 and 2 describe the preparation of the compound of formula I and its desired enantiomeric forms. The starting materials of formulae III and 1-benzyloxy-4-(2-chloro-ethoxy)-benzene are known compounds or can be prepared by methods known in the art. [0020]
  • In schemes 1 and 2 the following abbreviations have been used: [0021]
    Z—Cl benzylchloroformate
    MCPBA meta-chloroperbenzoic acid
    DMAP dimethylaminopyridine
    Pd/C palladium on carbon catalyst
    DMF dimethylformamide
    Bn benzyl
  • [0022]
    Figure US20010047014A1-20011129-C00006
  • wherein “hal” may be chloro or bromo. [0023]
    Figure US20010047014A1-20011129-C00007
  • The detailed description of the above mentioned processes is described in Examples 1-17. [0024]
  • As mentioned earlier, the compounds of formula I and their pharmaceutically acceptable addition salts possess valuable pharmacodynamic properties. They are NMDA-receptor subtype selective blockers, which have a key function in modulating neuronal activity and plasticity which makes them key players in mediating processes underlying development of CNS as well as learning and memory formation. [0025]
  • The compounds were investigated in accordance with the test given hereinafter. [0026]
  • Method 1 3H-Ro 25-6981 Binding(Ro 25-6981 is [R-(R*,S*)]-α-(4-Hydroxy-phenyl)-β-methyl-4-(phenyl-methyl)-1-piperidine propanol)
  • Male Füllinsdorf albino rats weighing between 150-200 g were used. Membranes were prepared by homogenization of the whole brain minus cerebellum and medulla oblongata with a Polytron (10,000 rpm, 30 seconds), in 25 volumes of a cold Tris-HCl 50 mM, EDTA 10 mM, pH 7.1 buffer. The homogenate was centrifuged at 48,000 g for 10 minutes at 4° C. The pellet was resuspended using the Polytron in the same volume of buffer and the homogenate was incubated at 37° C. for 10 minutes. After centrifugation the pellet was homogenized in the same buffer and frozen at −80° C. for at least 16 hours but not more than 10 days. For the binding assay the homogenate was thawed at 37° C., centrifuged and the pellet was washed three times as above in a Tris-HCl 5 mM, pH 7.4 cold buffer. The final pellet was resuspended in the same buffer and used at a final concentration of 200 μg of protein/ml. [0027]
  • [3H]-Ro 25-6981 binding experiments were performed using a Tris-HCl 50 mM, pH 7.4 buffer. For displacement experiments 5 nM of 3H-Ro 25-6981 were used and non specific binding was measured using 10 μM of tetrahydroisoquinoline and usually it accounts for 10% of the total. The incubation time was 2 hours at 4° C. and the assay was stopped by filtration on Whatman GF/B glass fiber filters (Unifilter-96, Packard, Zürich, Switzerland). The filters were washed 5 times with cold buffer. The radioactivity on the filter was counted on a Packard Top-count microplate scintillation counter after addition of 40 mL of microscint 40 (Canberra Packard S.A., Zürich, Switzerland). [0028]
  • The effects of compounds were measured using a minimum of 8 concentrations and repeated at least once. The pooled normalized values were analyzed using a non-linear regression calculation program which provide IC[0029] 50 with their relative upper and lower 95% confidence limits (RS1, BBN, USA).
  • Method 2 3H-Prazosin Binding
  • Male Füllinsdorf albino rats weighing between 150-200 g were used. Membranes were prepared by homogenization of the whole brain minus cerebellum and medulla oblongata with a Plytron (10,000 rpm, 30 seconds), in 25 volumes of a cold Tris-HCl 50 mM, EDTA 10 mM, pH 7.1 buffer. The homogenate was centrifuged at 48,000 g for 10 minutes at 4° C. The pellet was resuspended using the Polytron in the same volume of buffer and the homogenate was incubated at 37° C. for 10 minutes. After centrifugation the pellet was homogenized in the same buffer and frozen at −80° C. for at least 16 hours but not more than 10 days. For the binding assay the homogenate was thawed at 37° C., centrifuged and the pellet was washed three times as above in a Tris-HCl 5 mM, pH 7.4 cold buffer. The final pellet was resuspended in the same buffer and used at a final concentration of 200 mg of protein/ml. [0030]
  • 3H-Prazosin binding experiments were performed using a Tris-HCl 50 mM, pH 7.4 buffer. For displacement experiments 0.2 nM of 3H-Prazosine were used and non specific binding was measured using 100 mM of Chlorpromazine. The incubation time was 30 minutes at room temperature and the assay was stopped by filtration on Whatman GF/B glass fiber filters (Unifilter-96, Canberra Packard S.A., Zürich, Switzerland). The filters were washed 5 times with cold buffer. The radioactivity on the filter was counted on a Packard Top-count microplate scintillation counter after addition of 40 ml of microscint 40 (Canberra Packard S.A., Zürich, Switzerland). The effects of compounds were measured using a minimum of 8 concentrations and repeated at least once. The pooled normalized values were analyzed using a non-linear regression calculation program which provide IC[0031] 50 with their relative upper and lower 95% confidence limits (RS1, BBN, USA).
  • The thus-determined activity of compounds in accordance with the invention is in the range of 0.039-0.045 (in μM), as described in the table above. [0032]
  • Method 3 Methods for Studying the Inhibition of the hERG K+ Channel
  • CHO cells were stably transfected by a pcDNA3-hERG expression vector containing a SV40-neo cassette for selection. Cells were thinly plated into 35 mm dishes and used for the electrophysiological experiment [0033] ½-3 d later.
  • During the experiment the cells were continuously superfused with an extracellular saline containing (in mM): NaCl 150, KCl 10, MgCl[0034] 2 1, CaCl2 3, HEPES 10 (pH=7.3 by addition of NaOH). A 10-mM stock solution of the test compound was made from pure DMSO. Test solution were made by at least 1000-fold dilution of the stock solution into the extracellular saline. The glass micropipettes for whole-cell patch-clamp recording were filled with a containing (in mM): KCl 110, BAPTA 10, HEPES 10, MgCl2 4.5, Na2ATP 4, Na2-phosphocreatine 20, creatine kinase 200 μg/ml (pH=7.3 by addition of KOH).
  • The whole-cell configuration of the patch-clamp technique was used for the experiments. Cells were clamped to −80 mV holding potential and repetitively (0.1 Hz) stimulated by a voltage pulse pattern consisting of a 1-s conditioning depolarisation to 20 mV immediately followed by a hyperpolarisation of 50 ms duration to −120 mV. The membrane current was recorded for at least 3 min (18 stimuli) before compound application (control), and then for another two 3-min intervals in presence of two different concentrations of the compound. The current amplitudes (I[0035] test) at the end of each compound application interval were divided by the mean current amplitude (Icontrol) during the initial control period to calculate the percentage effect of the compound:
  • effect (%)=(1-I test /I control)·100.
  • Compound concentrations were chosen in decade steps (usually 1 and 10 μM) around the expected 50% inhibitory concentration (IC[0036] 50). If after the first experiment the IC50 turned out to lie outside the range between the two chosen concentrations the concentrations were changed to bracket the IC50 in the following experiments. The compound was tested on at least three cells. Its IC50 was then estimated from the population of all percent-effect values by non-linear regression using the function effect=100/(1−IC50/concentration)Hill). Concentrations higher than 10 μM were not tested. If 10 μM of the compound turned out to produce less than 50% effect, IC50 was labelled as “>10 μM” and the compound was characterised by the average effect seen at 10 μM.
  • The compounds of formula I and their salts, as herein described, together with pharmaceutically inert excipients are preferably incorporated into standard pharmaceutical dosage forms, for example, for oral or parenteral application with the usual pharmaceutical adjuvant materials, for example, organic or inorganic inert carrier materials, such as, water, gelatin, lactose, starch, magnesium stearate, talc, vegetable oils, gums, polyalkylene-glycols and the like. Examples of pharmaceutical preparations in solid form are tablets, suppositories, capsules, or in liquid form are solutions, suspensions or emulsions. Pharmaceutical adjuvant materials include preservatives, stabilizers, wetting or emulsifying agents, salts to change the osmotic pressure or to act as buffers. The pharmaceutical preparations can also contain other therapeutically active substances. [0037]
  • The daily dose of compounds of formula I to be administered varies with the particular compound employed, the chosen route of administration and the recipient. Representative of a method for administering the compounds of formula I is by the oral and parenteral type administration route. An oral formulation of a compound of formula I is preferably administered to an adult at a dose in the range of 1 mg to 1000 mg per day. A parenteral formulation of a compound of formula I is preferably administered to an adult at a dose in the range of from 5 to 500 mg per day. [0038]
  • The invention is further illustrated in the following examples. [0039]
  • EXAMPLE 1 4-Benzyl-4-hydroxy-piperidine-1-carboxylic Acid Benzyl Ester
  • To a solution of 5.0 g (26.2 mmol) of 4-hydroxybenzylpiperidine in 50 ml CH[0040] 2Cl2 were added under argon 5.5 ml (39.3 mmol) of Et3N and 3.7 ml (26.2 mmol) of benzylchloroformate at 0° C. After stirring the reaction mixture for 3 hours at r.t. 100 ml 1N HCl were added and the aqueous phase was extracted twice with CH2Cl2 and the combined organic layers were washed with 50 ml water, dried over MgSO4 and the solvent was removed under reduced pressure to give the crude product. Purification by chromatography over silica gel (hexane/ethyl acetate 4:1 to 2:1) yielded 3.9 g 4-benzyl-4-hydroxy-piperidine-1-carboxylic acid benzyl ester (11.9 mmol, 48%) as a yellow oil.
  • MS:m/e=326(M+1) [0041]
  • EXAMPLE 2 4-Benzyl-3,6-dihydro-2H-pyridine-1-carboxylic acid benzyl ester
  • To a solution of 40.0 g (123 mmol) of 4-benzyl-4-hydroxy-piperidine-1-carboxylic acid benzyl ester in 250 ml CH[0042] 2Cl2 were added 39.6 ml (492 mmol) pyridine and at 0° C. 17.8 ml (246 mmol) of SOCl2. The reaction mixture was stirred for 30 min. at 0° C. and then 250 ml of aqueous (2N) HCl were added. The aqueous phase was extracted twice with CH2Cl2 and the combined organic layers were washed with water, dried over MgSO4 and the solvent was removed under reduced pressure to give 36.3 g (118 mmol, 96%) of 4-benzyl-3,6-dihydro-2H-pyridine-1-carboxylic acid benzyl ester as an orange oil.
  • MS:m/e=308(M+1) [0043]
  • EXAMPLE 3 (1R,6S) and (1S,6R)-6-Benzyl-7-oxa-3-aza-bicyclo[4.1.0]heptane-3-carboxylic Acid Benzyl Ester
  • To a solution of 36.0 g (117 mmol) of 4-benzyl-3,6-dihydro-2H-pyridine-1-carboxylic acid benzyl ester in 250 ml CH[0044] 2Cl2 were added 40.9 g (166 mmol, ˜70%) MCPBA. The reaction mixture was stirred for 2 hours and a 1N NaOH-solution was added. The aqueous phase was extracted twice with CH2Cl2 and the combined organic layers were washed with 1 N NaOH, dried over MgSO4 and the solvent was removed under reduced pressure to give 37.6 g (116 mmol, 99%) of (1R,6S) and (1S,6R)-6-benzyl-7-oxa-3-aza-bicyclo[4.1.0]heptane-3-carboxylic acid benzyl ester as an oil.
  • MS:m/e=324(M+1) [0045]
  • EXAMPLE 4 (3R,4R) and (3S,4S)-4-Benzyl-3,4-dihydroxy-piperidine-1-carboxylic Acid Benzyl Ester
  • To a solution of 37.6 g (116 mmol) of (1R,6S) and (1S,6R)-6-benzyl-7-oxa-3-aza-bicyclo[4.1.0]heptane-3-carboxylic acid benzyl ester in 170 ml THF were added 37 ml H[0046] 2SO4 (10%). The reaction mixture was stirred for 16 hours and then concentrated under reduced pressure. The residue was dissolved in ethyl acetate and extracted with sat. NaHCO3. The aqueous phase was extracted twice with ethyl acetate and the combined organic layers were washed with sat. NaHCO3, dried over MgSO4 and the solvent was removed under reduced pressure to give 40.8 g (100%, purity ˜95%) of crude (3R,4R) and (3S,4S)-4-benzyl-3,4-dihydroxy-piperidine-1-carboxylic acid benzyl ester.
  • [0047] MS:m/e=342(M+1)
  • EXAMPLE 5 (4R, 4R), 4-Benzyl-4-hydroxy-3-((2S)-trifluoroacetyl-cyclopentanecarbonyloxy)-piperidine-1-carboxylic Acid Benzyl Ester
  • To a solution of 43.0 g (126 mmol) (3R,4R) and (3S,4S)-4-benzyl-3,4-dihydroxy-piperidine-1-carboxylic acid benzyl ester and 23.1 g (189 mmol) DMAP in 600 ml CH[0048] 2Cl2 were added dropwise under argon 500 ml (340 mmol, 0.70 N) (S)-N-trifluoroacetyl-prolinechloride. The reaction mixture was stirred for 16 hours at r.t. and then sat. NaHCO3 solution was added. The aqueous phase was extracted three times with CH2Cl2 and the combined organic layers were washed with sat. NaHCO3 and 1N HCl, dried over MgSO4 and the solvent was removed under reduced pressure to give the crude product. Purification by chromatography on silica gel (hexane:ethyl acetate 4:1 to 1:1) and crystallization from diethylether yielded 17.9 g (33 mmol, 27%) (3R,4R), 4-benzyl-4-hydroxy-3-(2S)-trifluoroacetyl-cyclopentanecarbonyloxy)-piperidine-1-carboxylic acid benzyl ester.
  • MS:m/e=535(M+1), (c=1.11, CH[0049] 2Cl2).
  • EXAMPLE 6 (3S,4S), 4-Benzyl-4-hydroxy-3-((2S)-trifluoroacetyl-cyclopentanecarbonyloxy)-piperidine-1-carboxylic acid benzyl ester
  • To a solution of 43.0 g (126 mmol) (3R,4R) and (3S,4S)-4-benzyl-3,4-dihydroxy-piperidine-1-carboxylic acid benzyl ester and 23.1 g (189 mmol) DMAP in 600 ml CH[0050] 2Cl2 were added under argon 500 ml (340 mmol, 0.70 N) (S)-N-trifluoroacetyl-prolinechloride dropwise. The reaction mixture was stirred for 16 hours at r.t. and then sat. NaHCO3 solution was added. The aqueous phase was extracted three times with CH2Cl2 and the combined organic layers were washed with sat. NaHCO3 and 1N HCl, dried over MgSO4 and the solvent was removed under reduced pressure to give the crude product. Purification by chromatography on silica gel (hexane:ethyl acetate 4:1 to 1:1) and crystallization from diethylether yielded 14.3 g (27 mmol, 21%) (3S,4S)-4-benzyl-4-hydroxy-3-((2s)-trifluoroacetyl-cyclopentanecarbonyloxy)-piperidine-1-carboxylic acid benzyl ester.
  • MS:m/e=535(M+1), (c=1.11, CH[0051] 2Cl2).
  • EXAMPLE 7 (3R,4R)-4-Benzyl-3,4-dihydroxy-piperidine-1-carboxylic acid benzyl ester
  • To a solution of 17.9 g (33.5 mmol) (3R), (4R), 4-benzyl-4-hydroxy-3-((2S)-trifluoroacetyl-cyclopentanecarbonyloxy)-piperidine-1-carboxylic acid benzyl ester in 500 ml EtOH were added 250 ml (250 mmol) of 1 N NaOH. The reaction mixture was stirred for 16 hours and water was then added. The aqueous phase was extracted three times with CH[0052] 2Cl2 and the combined organic layers were washed with water, dried over MgSO4 and the solvent was removed under reduced pressure to give 11.2 g (32.8 mmol, 98%) (3R, 4R)-4-benzyl-3,4-dihydroxy-piperidine-1-carboxylic acid benzyl ester as an oil.
  • MS:m/e=342.3(M+1), [α][0053] D 20=−36.75(c=1.02, CH2Cl2).
  • EXAMPLE 8 (3S,4S)-4-Benzyl-3,4-dihydroxy-piperidine-1-carboxylic acid benzyl ester
  • To a solution of 14.3 g (27 mmol) (3S,4S)-4-benzyl-4-hydroxy-3-((2S)-trifluoroacetyl-cyclopentanecarbonyloxy)-piperidine-1-carboxylic acid benzyl ester in 500 ml EtOH were added 250 ml (250 mmol) 1 N NaOH. The reaction mixture was stirred for 16 hours and water was added. The aqueous phase was extracted three times with CH[0054] 2Cl2 and the combined organic layers were washed with water, dried over MgSO4 and the solvent was removed under reduced pressure to give 8.4 g (25 mmol, 92%) (3S,4S)-4-benzyl-3,4-dihydroxy-piperidine-1-carboxylic acid benzyl ester as an oil.
  • MS:m/e=342.3(M+1), [α][0055] D 20=35.30(c=1.02, CH2Cl2).
  • EXAMPLE 9 (3R,4R) and (3S,4S)-4-Benzyl-3,4-dihydroxy-piperidine
  • (3R,4R) and (3S,4S)-4-Benzyl-3,4-dihydroxy-piperidine-1-carboxylic acid benzyl ester 1.46 g (4.3 mmol) was dissolved in 30 ml EtOH and hydrogenated in the presence of 400 mg Pd/C (10%) under atmospheric pressure of H[0056] 2 at r.t. After 16 hours the reaction was complete and the catalyst was filtered off and the solvent was removed under reduced pressure to give 796 mg (3.8 mmol, 89%) (3R,4R) and (3S,4S)-4-benzyl-3,4-dihydroxy-piperidine as an oil.
  • MS:m/e=207.1(M). [0057]
  • EXAMPLE 10 (3R,4R)-4-Benzyl-3,4-dihydroxy-piperidine
  • (3R,4R)-4-benzyl-3,4-dihydroxy-piperidine-1-carboxylic acid benzyl ester 11.0 g (32 mmol) was dissolved in 250 ml EtOH and hydrogenated in the presence of 1.1 g Pd/C (10%) under atmospheric pressure of H[0058] 2 at r.t. After 16 hours the reaction was complete and the catalyst was filtered off and the solvent was removed under reduced pressure to give 6.6 g (32 mmol, 100%) (3R,4R)-4-benzyl-3,4-dihydroxy-piperidine as an oil.
  • MS:m/e=207.1(M), [α][0059] D 20=−42.3(c=1.00, ethanol).
  • EXAMPLE 11 (3S), (4S)-4-Benzyl-3,4-dihydroxy-piperidine
  • (3S,4S)-4-Benzyl-3,4-dihydroxy-piperidine-1-carboxylic acid benzyl ester 8.2 g (24 mmol) was dissolved in 250 ml EtOH and hydrogenated in the presence of 1.1 g Pd/C, (10%)under atmospheric pressure at r.t. After 16 hours the reaction was complete and the catalyst was filtered off and the solvent was removed under reduced pressure to give 5.5 g (quant., ˜95% purity) (3S,4S)-4-Benzyl-3,4-dihydroxy-piperidine as an oil. [0060]
  • MS:m/e=207.1(M), [α][0061] D 20=+42.57 (c=1.05, ethanol).
  • EXAMPLE 12 (3R,4R) and (3S,4S)-4-Benzyl-1-[2-(4-benzyloxy-phenoxy)-ethyl]-piperidine-3,4-diol
  • To a solution of 0.2 g (1.0 mmol) (3R,4R) and (3S,4S)-4-benzyl-3,4-dihydroxy-piperidine in 10 ml DMF were added 297 mg (1.0 mmol) 1-benzyloxy-4-(2-chloro-ethoxy)-benzene and 0.2 g (1.5 mmol) K[0062] 2CO3 and the reaction mixture was heated to 90° C. for 16 hours. After the addition of water, the aqueous phase was extracted three times with ethyl acetate and the combined organic layers were washed with water, dried over MgSO4 and the solvent was removed under reduced pressure to give 551 mg (100%, ˜80% purity) (3R,4R) and (3S,4S)-4-benzyl-1-[2-(4-benzyloxy-phenoxy)-ethyl]-piperidine-3,4-diol as a solid.
  • MS:m/e=434.5(M+1). [0063]
  • EXAMPLE 13 (3R,4R)-4-Benzyl-1-[2-(4-benzyloxy-phenoxy)-ethyl]-piperidine-3,4-diol
  • To a solution of 5.0 g (24 mmol) (3R,4R)-4-benzyl-3,4-dihydroxy-piperidine in 150 ml DMF were added 7.4 g (24 mmol) 1-benzyloxy-4-(2-chloro-ethoxy)-benzene and 5.0 g (36 mmol) K[0064] 2CO3 and the reaction mixture was heated to 90° C. for 72 hours. After the addition of water the aqueous phase was extracted three times with ethyl acetate and the combined organic layers were washed with water, dried over MgSO4 and the solvent was removed under reduced pressure to give 10.5 g (24 mmol, 100%) (3R,4R)-4-benzyl-1-[2-(4-benzyloxy-phenoxy)-ethyl]-piperidine-3,4-diol as a solid.
  • MS:m/e=434.5(M+1), [α][0065] D 20=−27.5 (c=0.95, CH2Cl2).
  • EXAMPLE 14 (3S,4S)-4-Benzyl-1-[2-(4-benzyloxy-phenoxy)-ethyl]-piperidine-3,4-diol
  • To a solution of 5.0 g (24 mmol) (3S,4S)-4-benzyl-3,4-dihydroxy-piperidine in 150 ml DMF were added 7.4 g (24 mmol) 1-benzyloxy-4-(2-chloro-ethoxy)-benzene and 5.0 g (36 mmol) K[0066] 2CO3 and the reaction mixture was heated to 90° C. for 72 hours. After the addition of water the aqueous phase was extracted three times with ethyl acetate and the combined organic layers were washed with water, dried over MgSO4 and the solvent was removed under reduced pressure to give 10.9 g (quant., ˜95% purity) (3S,4S)-4-benzyl-1-[2-(4-benzyloxy-phenoxy)-ethyl]-piperidine-3,4-diol as a solid.
  • MS:m/e=434.5(M+1), [α][0067] D 20=+26.2(c=1.04, CH2Cl2).
  • EXAMPLE 15 (3R,4R) and (3S,4S)-4-Benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidine-3,4-diol
  • (3R,4R) and (3 S,4S)-4-benzyl-1-[2-(4-benzyloxy-phenoxy)-ethyl]-piperidine-3,4-diol 550 mg (1.3 mmol) was dissolved in 10 ml EtOH and hydrogenated in the presence of 100 mg Pd/C (10%) under atmospheric pressure at 50° C. After 4 hours the reaction was complete and the catalyst was filtered off and the solvent was removed under reduced pressure to give the crude product. Purification by chromatography (CH[0068] 2Cl2/MeOH 9:1) yielded 249 mg (0.73 mmol, 56%) (3R,4R) and (3S,4S)-4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidine-3,4-diol as a solid.
  • MS:m/e=344.4(M+1). [0069]
  • EXAMPLE 16 (3R,4R)-4-Benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidine-3,4-diol
  • (3R,4R)-4-benzyl-1-[2-(4-benzyloxy-phenoxy)-ethyl]-piperidine-3,4-diol 10.3 g (24 mmol) was dissolved in 300 ml EtOH and hydrogenated in the presence of 1.1 g Pd/C (10%) under atmospheric pressure at 50° C. After 4 hours the reaction was complete and the catalyst was filtered off and the solvent was removed under reduced pressure to give the crude product. Purification by chromatography (CH[0070] 2Cl2/MeOH 10:1) and crystallization from ethyl acetate and hexane yielded then 4.6 g (10.6 mmol, 45%) (3R,4R)-4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidine-3,4-diol as a solid.
  • MS:m/e=344.4(M+1), [α][0071] D 20=−36.2(c=1.03, CH2Cl2).
  • EXAMPLE 17 (3S,4S)-4-Benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidine-3,4-diol
  • (3S,4S)-4-Benzyl-1-[2-(4-benzyloxy-phenoxy)-ethyl]-piperidine-3,4-diol 10.3 g (24 mmol) was dissolved in 300 ml EtOH and hydrogenated in the presence of 1.1 g Pd/C (10%) under atmospheric pressure at 50° C. After 4 hours the reaction was complete and the catalyst was filtered off and the solvent was removed under reduced pressure to give the crude product. Purification by chromatography (CH[0072] 2Cl2/MeOH 10:1) and crystallization from ethyl acetate and hexane yielded then 5.7 g (16.6 mmol, 69%) (3S,4S)-4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidine-3,4-diol as a solid.
  • MS:m/e=344.3(M+1), [α][0073] D 20=+37.1(c1.04, CH2Cl2).
    Tablet Formulation (Wet Granulation)
    Ingredients mg/tablet
    1. Active compound 5 25 100 500
    2. Lactose Anhydrous DTG 125 105 30 150
    3. Sta-Rx 1500 6 6 6 30
    4. Microcrystalline Cellulose 30 30 30 150
    5. Magnesium Stearate 1 1 1 1
    TOTAL 167 167 167 831
  • [0074]
    Capsule Formulation
    Ingredients mg/capsule
    1. Active compound 5 25 100 500
    2. Hydrous Lactose 159 123 148
    3. Corn Starch 25 35 40 70
    4. Talc 10 15 10 25
    5. Magnesium Stearate 1 2 2 5
    TOTAL 200 200 300 600

Claims (11)

1. A compound with the structure of formula I
Figure US20010047014A1-20011129-C00008
its R,R- and S,S-enantiomers and their pharmaceutically acceptable acid addition salts.
2. A compound of formula I in accordance with
claim 1
, selected from the group consisting of (3R, 4R) 4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidine-3,4-diol, (3S, 4S) 4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidine-3,4-diol and racemic mixtures thereof.
3. A compound of formula I in accordance with
claim 2
, which is (3 R,4R)-4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl] -piperidine-3,4-diol.
4. A compound of formula I in accordance with
claim 2
, which is (3S,4S)-4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidine-3,4-diol.
5. A medicament containing one or more compounds according to
claim 2
and pharmaceutically inert excipients.
6. A medicament in accordance with
claim 5
useful for the treatment of diseases including disease states caused by overactivation of respective NMDA receptor subtypes including acute forms of neurodegeneration caused by stroke or brain trauma; chronic forms of neurodegeneration such as Alzheimer's disease, Parkinson's disease, Huntington's disease or ALS (amyotrophic lateral sclerosis); neurodegeneration associated with bacterial or viral infections, and, diseases such as schizophrenia, anxiety, depression and chronic/acute pain.
7. A process for preparing a compound of formula I as defined in
claim 1
, which process comprises
reacting a compound of formula
Figure US20010047014A1-20011129-C00009
with a compound of formula
Figure US20010047014A1-20011129-C00010
and deprotecting the hydroxy group to give compounds of formulae
Figure US20010047014A1-20011129-C00011
8. The method of
claim 7
further comprising reacting the compounds obtained with pharmaceutically acceptable inorganic and organic acids thereby forming addition salts.
9. The method of
claim 8
wherein said pharmaceutically acceptable acids are selected from the group consisting of hydrochloric acid, nitric acid, sulfuric acid, lactic acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methane-sulfonic acid, and p-toluenesulfonic acid.
10. A method of treatment of a disease state caused by malfunction of the NMDA receptor subtypes comprising administering to a patient in need of such treatment, an effective amount of a composition for treating said disease state, said composition containing an effective amount of a compound that functions as a NDMA receptor subtype specific blocker in a pharmaceutically acceptable carrier, said compound having the structure of formula I
Figure US20010047014A1-20011129-C00012
11. The method of treatment of
claim 10
wherein the disease state being treated consists of acute forms of neurodegeneration caused by stroke or brain trauma; chronic forms of neurodegeneration such as Alzheimer's disease, Parkinson's disease, Huntington's disease or ALS (amyotrophic lateral sclerosis); neurodegeneration associated with bacterial or viral infections, and, diseases such as schizophrenia, anxiety, depression and chronic/acute pain.
US09/811,888 2000-04-25 2001-03-19 Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists Expired - Fee Related US6432985B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP00108769.1 2000-04-25
EP00108769 2000-04-25
EP00108769 2000-04-25

Publications (2)

Publication Number Publication Date
US20010047014A1 true US20010047014A1 (en) 2001-11-29
US6432985B2 US6432985B2 (en) 2002-08-13

Family

ID=8168543

Family Applications (1)

Application Number Title Priority Date Filing Date
US09/811,888 Expired - Fee Related US6432985B2 (en) 2000-04-25 2001-03-19 Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists

Country Status (18)

Country Link
US (1) US6432985B2 (en)
EP (1) EP1278730B1 (en)
JP (1) JP3831255B2 (en)
KR (1) KR100527527B1 (en)
CN (1) CN1178914C (en)
AR (1) AR028357A1 (en)
AT (1) AT313527T (en)
AU (1) AU785153B2 (en)
BR (1) BR0110233A (en)
CA (1) CA2407345C (en)
DE (1) DE60116080T2 (en)
DK (1) DK1278730T3 (en)
ES (1) ES2254422T3 (en)
MX (1) MXPA02010573A (en)
PE (1) PE12292001A1 (en)
UY (1) UY26681A1 (en)
WO (1) WO2001081309A2 (en)
ZA (1) ZA200208134B (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097637A1 (en) * 2002-05-16 2003-11-27 F. Hoffmann-La Roche Ag (imidazol-1-yl-methyl)-pyridazine as nmda receptor blocker
US20100048713A1 (en) * 2006-01-06 2010-02-25 Aarhus Universitet Compounds acting on the serotonin transporter
US7684859B2 (en) 2002-04-25 2010-03-23 Brainsgate Ltd. Stimulation of the OTIC ganglion for treating medical conditions
US7860569B2 (en) 2007-10-18 2010-12-28 Brainsgate, Ltd. Long-term SPG stimulation therapy for prevention of vascular dementia
US20110160623A1 (en) * 2004-02-20 2011-06-30 Brainsgate Ltd. External stimulation of the spg
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
US8229571B2 (en) 2002-11-14 2012-07-24 Brainsgate Ltd. Greater palatine canal stylet
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
US9675796B2 (en) 2013-11-10 2017-06-13 Brainsgate Ltd. Implant and delivery system for neural stimulator
US10271907B2 (en) 2015-05-13 2019-04-30 Brainsgate Ltd. Implant and delivery system for neural stimulator

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0811844A2 (en) * 2007-05-21 2014-11-18 Reviva Pharmaceuticals Inc The compound and method for treating a patient
US8008253B2 (en) 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
NZ588698A (en) * 2008-03-27 2012-06-29 Evotec Neurosciences Gmbh Methods for treating disorders using nmda nr2b-subtype selective antagonist
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
KR20180053432A (en) * 2008-08-12 2018-05-21 진판델 파마슈티컬스 인코포레이티드 Method of identifying disease risk factors
MX355479B (en) 2011-01-10 2018-04-19 Zinfandel Pharmaceuticals Inc Methods and drug products for treating alzheimer's disease.
US8703763B2 (en) * 2011-03-02 2014-04-22 Hoffmann-La Roche Inc. Bridged piperidine derivatives
AR110122A1 (en) * 2016-11-08 2019-02-27 Hoffmann La Roche Fenoxitriazoles

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
ZA9610745B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
TW498067B (en) 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7684859B2 (en) 2002-04-25 2010-03-23 Brainsgate Ltd. Stimulation of the OTIC ganglion for treating medical conditions
US20030229096A1 (en) * 2002-05-16 2003-12-11 Bernd Buettelmann Substituted imidazol-pyridazine derivatives
US7005432B2 (en) 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
WO2003097637A1 (en) * 2002-05-16 2003-11-27 F. Hoffmann-La Roche Ag (imidazol-1-yl-methyl)-pyridazine as nmda receptor blocker
US8229571B2 (en) 2002-11-14 2012-07-24 Brainsgate Ltd. Greater palatine canal stylet
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
US8954149B2 (en) 2004-02-20 2015-02-10 Brainsgate Ltd. External stimulation of the SPG
US20110160623A1 (en) * 2004-02-20 2011-06-30 Brainsgate Ltd. External stimulation of the spg
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
US8406869B2 (en) 2005-08-19 2013-03-26 Brainsgate, Ltd. Post-acute electrical stimulation treatment of adverse cerebrovascular events
US8958881B2 (en) 2005-08-19 2015-02-17 Brainsgate Ltd. Neuroprotective electrical stimulation
US20100048713A1 (en) * 2006-01-06 2010-02-25 Aarhus Universitet Compounds acting on the serotonin transporter
US7860569B2 (en) 2007-10-18 2010-12-28 Brainsgate, Ltd. Long-term SPG stimulation therapy for prevention of vascular dementia
US9675796B2 (en) 2013-11-10 2017-06-13 Brainsgate Ltd. Implant and delivery system for neural stimulator
US10271907B2 (en) 2015-05-13 2019-04-30 Brainsgate Ltd. Implant and delivery system for neural stimulator

Also Published As

Publication number Publication date
MXPA02010573A (en) 2003-03-10
AR028357A1 (en) 2003-05-07
PE12292001A1 (en) 2001-12-08
EP1278730A2 (en) 2003-01-29
UY26681A1 (en) 2001-10-25
DK1278730T3 (en) 2006-05-01
US6432985B2 (en) 2002-08-13
EP1278730B1 (en) 2005-12-21
WO2001081309A2 (en) 2001-11-01
CA2407345A1 (en) 2001-11-01
WO2001081309A3 (en) 2002-01-17
BR0110233A (en) 2003-01-21
ZA200208134B (en) 2004-01-22
KR20040007216A (en) 2004-01-24
DE60116080D1 (en) 2006-01-26
ES2254422T3 (en) 2006-06-16
CN1178914C (en) 2004-12-08
JP2004509837A (en) 2004-04-02
AU785153B2 (en) 2006-10-05
DE60116080T2 (en) 2006-08-24
AU6021301A (en) 2001-11-07
CN1443166A (en) 2003-09-17
CA2407345C (en) 2009-04-07
KR100527527B1 (en) 2005-11-09
AT313527T (en) 2006-01-15
JP3831255B2 (en) 2006-10-11

Similar Documents

Publication Publication Date Title
DE60021371T2 (en) antagonists piperidine derivatives useful as CCR5
US5750540A (en) 1,4-di-substituted piperidine derivatives
DE60125335T2 (en) Azacyclic compounds for use in the treatment of related diseases with serotonin
RU2125051C1 (en) Derivatives of diphenyl, derivative of phenylpiperazine, method of patients treatment
DE60112791T2 (en) Piperidine mch antagonists and their use in the treatment of obesity
FI114475B (en) Process for the preparation of novel therapeutically useful kinuklidiinijohdannaisten
DE69918687T2 (en) 4-phenylpiperidines for the treatment of pruritic skin disorders
DE60012223T2 (en) Urea derivatives effective as muscarinic receptor antagonist
US20060122197A1 (en) Amido compounds and their use as pharmaceuticals
EP0869792B1 (en) 4-substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
US8288417B2 (en) N-substituted piperidines and their use as pharmaceuticals
DE69730345T2 (en) Triarylethanderivate as PDE IV inhibitors
KR100238343B1 (en) Novel n-(3, 4-dichlorophenyl-propyl)-piperidine derivatives as selective human nk3-receptor antagonists
DE60116761T2 (en) adamantane
CN100482646C (en) Derivative of n-[phenyl(piperidin-2-yl)methyl]benzamide, the preparation method thereof and application of same in therapeutics
DE60012031T2 (en) Piperazine compounds as tachykinin antagonists
DE60225162T2 (en) Phenylpiperazine as serotonin reuptake inhibitors
US6812236B2 (en) Compounds useful in therapy
DE69912379T2 (en) Antithrombotic agents
DE602004006431T2 (en) Derivatives of n-äheteroaryl (piperidin-2-yl) methylübenzamid, processes for their preparation and their application in therapeutics
US20050261290A1 (en) Novel compounds of proline and morpholine derivatives
US4943578A (en) Piperazine compounds
DE60034155T2 (en) Adamantane derivatives for the treatment of inflammatory, immunological and cardiovascular diseases
US7951821B2 (en) N-[phenyl(piperidin-2-yl)methyl]benzamide derivatives, preparation thereof, and use thereof in therapy
US20040209872A1 (en) Calcium channel blockers comprising two benzhydril moieties

Legal Events

Date Code Title Description
AS Assignment

Owner name: F. HOFFMANN-LA ROCHE AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ALANINE, ALEXANDER;BUETTELMANN, BERND;HEITZ NEIDHART, MARIE-PAULE;AND OTHERS;REEL/FRAME:011833/0516

Effective date: 20010306

Owner name: HOFFMANN-LA ROCHE INC., NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:F. HOFFMANN-LA ROCHE AG;REEL/FRAME:011833/0721

Effective date: 20010307

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Expired due to failure to pay maintenance fee

Effective date: 20140813